TSX:APS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Aptose Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APS is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: APS's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

6.6%

APS

4.9%

CA Biotechs

2.8%

CA Market


1 Year Return

128.8%

APS

80.8%

CA Biotechs

-0.3%

CA Market

Return vs Industry: APS exceeded the Canadian Biotechs industry which returned 76.8% over the past year.

Return vs Market: APS exceeded the Canadian Market which returned -0.5% over the past year.


Shareholder returns

APSIndustryMarket
7 Day6.6%4.9%2.8%
30 Day33.4%24.7%10.0%
90 Day16.2%25.8%5.7%
1 Year128.8%128.8%80.8%80.8%3.3%-0.3%
3 Year214.1%214.1%18.5%18.5%12.2%1.3%
5 Year137.4%137.4%6.0%6.0%49.1%26.2%

Long-Term Price Volatility Vs. Market

How volatile is Aptose Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aptose Biosciences undervalued compared to its fair value and its price relative to the market?

4.37x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate APS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APS is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: APS is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APS is good value based on its PB Ratio (4.4x) compared to the CA Biotechs industry average (6.2x).


Next Steps

Future Growth

How is Aptose Biosciences forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

8.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if APS's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if APS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aptose Biosciences performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APS is currently unprofitable.

Growing Profit Margin: APS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APS is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.

Accelerating Growth: Unable to compare APS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: APS has a negative Return on Equity (-37.35%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aptose Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: APS's short term assets ($133.9M) exceed its short term liabilities ($5.4M).

Long Term Liabilities: APS's short term assets ($133.9M) exceed its long term liabilities ($658.0K).


Debt to Equity History and Analysis

Debt Level: APS is debt free.

Reducing Debt: APS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: APS has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 21.7% each year.


Next Steps

Dividend

What is Aptose Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APS's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

William Rice (61 yo)

7.08yrs

Tenure

US$1,511,896

Compensation

Dr. William G. Rice, Ph.D., has been the Chief Executive Officer and President of Aptose Biosciences Inc. since October 28, 2013. Dr. Rice served as the President and Chief Executive Officer of Cylene Phar...


CEO Compensation Analysis

Compensation vs Market: William's total compensation ($USD1.51M) is above average for companies of similar size in the Canadian market ($USD908.86K).

Compensation vs Earnings: William's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
William Rice
Chairman7.08yrsUS$1.51m0.33%
$ 2.4m
Gregory Chow
Executive VP6.92yrsUS$1.05m0.26%
$ 1.9m
Jotin Marango
Senior VP & Chief Business Officer1.42yrsUS$1.09m0.13%
$ 927.5k
Rafael Bejar
Senior VP & Chief Medical Officer0.83yrno datano data

4.2yrs

Average Tenure

47.5yo

Average Age

Experienced Management: APS's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Rice
Chairman7.08yrsUS$1.51m0.33%
$ 2.4m
Mark Vincent
Independent Director13.17yrsUS$103.63k0.0073%
$ 51.8k
Denis Burger
Lead Independent Directorno dataUS$136.63k0.018%
$ 129.7k
Stephen Howell
Member of Scientific Advisory Boardno datano datano data
Daniel Von Hoff
Member of Scientific Advisory Boardno datano datano data
Erich Platzer
Independent Director5.92yrsUS$99.63k0.15%
$ 1.1m
Warren Whitehead
Independent Director9.58yrsUS$106.63k0.045%
$ 319.2k
Caroline Loewy
Independent Director2.58yrsUS$107.63k0%
$ 0
Brian Druker
Chairman of Scientific Advisory Board7.08yrsno datano data
Michael Andreeff
Member of Scientific Advisory Board5.67yrsno datano data
Carol Ashe
Independent Director2.25yrsUS$107.63k0%
$ 0

6.5yrs

Average Tenure

67.5yo

Average Age

Experienced Board: APS's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.2%.


Top Shareholders

Company Information

Aptose Biosciences Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aptose Biosciences Inc.
  • Ticker: APS
  • Exchange: TSX
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$709.117m
  • Shares outstanding: 88.86m
  • Website: https://www.aptose.com

Number of Employees


Location

  • Aptose Biosciences Inc.
  • 251 Consumers Road
  • Suite 1105
  • Toronto
  • Ontario
  • M2J 4R3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APTONasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJun 1992
APSTSX (The Toronto Stock Exchange)YesCommon SharesCACADJun 1992
LTIADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 1992
0UI8LSE (London Stock Exchange)YesCommon SharesGBCADJun 1992

Biography

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 00:28
End of Day Share Price2020/11/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.